Sugi Predict

Sugi Predict / Targets / SETDB1

SETDB1

Histone-lysine N-methyltransferase SETDB1 · Q15047 · SETDB1 on Sugi Atlas →

1,960 patent compounds predicted against SETDB1, 1,167 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3410039 SCHEMBL3410039 0.59 5/20
SCHEMBL11572432 SCHEMBL11572432 0.56 5/20
SCHEMBL14635966 SCHEMBL14635966 0.56 5/20
SCHEMBL12251211 SCHEMBL12251211 0.55 5/20
SCHEMBL14224747 SCHEMBL14224747 0.50 5/20
SCHEMBL9408745 SCHEMBL9408745 0.47 5/20
SCHEMBL7819612 SCHEMBL7819612 0.39 5/20
SCHEMBL540605 SCHEMBL540605 0.57 4/20
SCHEMBL13104293 SCHEMBL13104293 0.56 4/20
SCHEMBL11571347 SCHEMBL11571347 0.47 4/20
SCHEMBL11572084 SCHEMBL11572084 0.47 4/20
SCHEMBL14960629 SCHEMBL14960629 0.44 4/20
SCHEMBL16136320 SCHEMBL16136320 0.44 4/20
SCHEMBL12128721 SCHEMBL12128721 0.42 4/20
SCHEMBL7049168 SCHEMBL7049168 0.40 4/20
SCHEMBL4467278 SCHEMBL4467278 0.57 3/20
SCHEMBL6248360 SCHEMBL6248360 0.55 3/20
SCHEMBL1477497 SCHEMBL1477497 0.43 3/20
SCHEMBL8649748 SCHEMBL8649748 0.40 3/20
SCHEMBL14300087 SCHEMBL14300087 0.40 3/20

Clinical trials — most relevant to SETDB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC) PHASE1/PHASE2COMPLETED
Decitabine in Treating Patients With Myelofibrosis PHASE2ACTIVE_NOT_RECRUITING
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
FdCyd and THU for Advanced Solid Tumors PHASE1COMPLETED
The Efficacy of Allo-HSCT in ND HR-CBF-AML nanRECRUITING
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Mechanisms of Immune Deficiency nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. nanUNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
SRSF2 Gene Mutation in Patients With t-MDS/AML nanCOMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SETDB1 binder may also engage these)

ProteinNameSimilarity
O88974 — 1.000 O88974 →
Q08BR4 — 0.992 Q08BR4 →
Q6INA9 — 0.987 Q6INA9 →
Q80TJ7 — 0.987 Q80TJ7 →
Q9WTU0 — 0.986 Q9WTU0 →
P49140 — 0.986 P49140 →
Q8K2L8 — 0.986 Q8K2L8 →
KAT2B Histone acetyltransferase KAT2B 0.985 landscape →
Q5XJV7 — 0.984 Q5XJV7 →
Q62925 — 0.984 Q62925 →
Q5R6Y9 — 0.983 Q5R6Y9 →
Q28C33 — 0.983 Q28C33 →
Q8WYQ5 — 0.983 Q8WYQ5 →
Q69Z66 — 0.983 Q69Z66 →
Q5RF77 — 0.983 Q5RF77 →
Q8N5Y2 — 0.982 Q8N5Y2 →
Q5VUG0 — 0.982 Q5VUG0 →
Q921C3 — 0.982 Q921C3 →
Q5DTW2 — 0.982 Q5DTW2 →
Q7TN31 — 0.982 Q7TN31 →
A6QR44 — 0.982 A6QR44 →
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 0.982 landscape →
Q9EQM6 — 0.981 Q9EQM6 →
Q64127 — 0.981 Q64127 →
PHF8 Histone lysine demethylase PHF8 0.981 landscape →
Q6AI12 — 0.981 Q6AI12 →
TRIM24 Transcription intermediary factor 1-alpha 0.981 landscape →
Q8K4S7 — 0.981 Q8K4S7 →
Q9C0A6 — 0.981 Q9C0A6 →
B2RUR8 — 0.981 B2RUR8 →